Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19낭포성 섬유증 환자를 위한 생리학적 기반 약동학 주도 지침Article Published on 2022-06-012022-09-11 Journal: Clinical Pharmacology and Therapeutics [Category] 변종, [키워드] Administered approach AUC CFTR Combination coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection Cystic cystic fibrosis cytochrome P450 Day decrease dose drug interaction drug-drug interaction elexacaftor eliminated evaluated fibrosis independent information inhibited inhibiting inhibitor inhibitory effect ivacaftor metabolism modeling modulating Nirmatrelvir P450 parameter pharmacokinetic pharmacokinetics physiological predict predicted reduced regimen risk Ritonavir Simulation Taking tezacaftor therapeutic Therapies transmembrane Treatment was performed [DOI] 10.1002/cpt.2585 PMC 바로가기 [Article Type] Article
[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination][니르마트렐비르와 리토나비르(팍슬로비드)의 강력한 SARS-CoV-2 3CLpro 프로테아제 억제제 조합]Review Published on 2022-06-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] 3CL 3CLpro Administered adverse effects Antiviral antiviral drug antiviral drugs antiviral efficacy approved average conserved coronavirus Coronaviruses death duration of treatment effective Effectiveness EMA English FDA Final Hospitalization IMPROVE indican inhibitory activity media metabolism Modification Nirmatrelvir NSP11 Pandemia pandemic Patient Paxlovid PF-07321332 polyproteins pp1a pp1ab processing protease Protease inhibitor Proteases Proteins reducing risk Ritonavir SARS-CoV-1 SARS-CoV-2 sequence shown Spanish therapeutic target Treatment Viral variants [DOI] 10.37201/req/002.2022 PMC 바로가기 [Article Type] Review
In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale ApproachSARS-CoV-2에 대한 Paxlovid의 약리학의 실리코 평가: 다중 규모 접근Article Published on 2022-05-202022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 치료제, [키워드] agent agent-based model Antiviral approach cause component computation diffusion diffusion coefficient feature highest identify in silico in vitro in vivo Intervention mathematical multiscale mathematical modeling Nirmatrelvir outcome Paxlovid Pharmacometrics present profiles replicate Ritonavir SARS-CoV-2 sensitivity spatio-temporal dynamics temporal dynamics tissue damage virus virus diffusion. [DOI] 10.3390/v14051103 PMC 바로가기 [Article Type] Article
Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease질량 분석 분석은 SARS-CoV-2 파파인 유사 프로테아제에 대한 억제 프로필의 불일치를 보여줍니다Article Published on 2022-05-042022-09-11 Journal: ChemMedChem [Category] COVID19(2023년), SARS, 치료제, [키워드] applied assays auranofin clinical development cysteine functional highlighting in vitro inhibit inhibition inhibitor inhibitors M pro mass mass spectrometry mechanisms MONITOR MPro Nirmatrelvir non-structural proteins Nucleophilic cysteine protease Papain Papain-like protease PF-07321332 PF-07321332/nirmatrelvir PLPro profile protease protease inhibition Proteases reported SARS-CoV-2 SARS-CoV-2 main protease SARS-CoV-2 main protease/Mpro SARS-CoV-2 papain-like protease/PLpro selected selective targets the SARS-CoV-2 utility viral protease inhibition. viral replication [DOI] 10.1002/cmdc.202200016 PMC 바로가기 [Article Type] Article
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?COVID-19와 소분자 치료제의 약속: 배워야 할 교훈이 있습니까?Review Published on 2022-05-012022-09-11 Journal: Pharmacological research [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant therapy Antiviral antiviral agent Antiviral agents antivirals Baricitinib Baricitinib (PubChem CID: 44205240) Chloroquine Chloroquine (PubChem CID: 2719) coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical developmental Dexamethasone Dexamethasone (PubChem CID: 5743) drug Drug discovery effective Endemic Healthcare professional healthcare professionals Hydroxychloroquine Hydroxychloroquine (PubChem CID: 3652) Inclusion Ivermectin Ivermectin (PubChem CID: 6321424) limitation Lopinavir Lopinavir (PubChem CID: 92727) molnupiravir Molnupiravir (Pubchem CID: 145996610) Nirmatrelvir Nirmatrelvir (PubChem CID: 155903259) pandemic provided PubChem Remdesivir Remdesivir (PubChem CID: 121304016) researcher Retrospective analysis Ritonavir Ritonavir (PubChem CID: 392622) SARS-CoV-2 severe acute respiratory syndrome Coronavirus small molecule Small molecule therapeutics. standstill tested the disease therapy Treatment treatment of COVID-19 while with COVID-19 [DOI] 10.1016/j.phrs.2022.106201 PMC 바로가기 [Article Type] Review
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvirSARS-CoV-2 변이체의 주요 프로테아제 돌연변이체는 여전히 니르마트렐비르에 감수성입니다Article Published on 2022-04-152022-09-11 Journal: Bioorganic & medicinal chemistry letters [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] anticipated antiviral agent Antiviral agents B.1.1.529 B.1.351 Beta catalytically competent Coronaviral COVID-19 COVID-19 pandemic drug target Effectiveness Efficacy expressed in vitro data inhibitor inhibitors Lambda M pro main protease Missense mutation Multiple multiple mutations mutant Mutation Nirmatrelvir not compromised omicron P.2 PF-07321332 prevalent protease public health threat SARS-CoV-2 SARS-CoV-2 lineage SARS-CoV-2 variant Specific Spike protein susceptible the spike protein Vaccines variant variants variants of SARS-CoV-2 wildtype [DOI] 10.1016/j.bmcl.2022.128629 PMC 바로가기 [Article Type] Article
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19코비드-19를 가진 고위험, 입원하지 않은 성인을 위한 경구 NirmatrelvirClinical Trial Published on 2022-04-142022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료제, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus adjusted Administered adverse event adverse events Analysis assigned conducted Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 death deaths diarrhea double-blind drug dysgeusia enhancer evaluated Final final analysis high risk Hospitalization in vitro incidence inhibitor initiated interim analysis log M pro mean difference milliliter modified intention-to treat modified intention-to-treat Nirmatrelvir occurred onset of symptoms oral Patient patients patients treated Pfizer pharmacokinetic Placebo placebo group progression protease randomization randomized, controlled trial receive Relative risk risk risk reduction Ritonavir Serious Adverse Events severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 symptom onset symptomatic symptomatic COVID-19 the placebo group Treatment treatment period two group two groups Viral load [DOI] 10.1056/NEJMoa2118542 PMC 바로가기 [Article Type] Clinical Trial
Nirmatrelvir Plus Ritonavir: First ApprovalNirmatrelvir Plus Ritonavir: 첫 번째 승인Review Published on 2022-04-012022-09-11 Journal: Drugs [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval authorization Combination coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Emergency use HIV-1 Human immunodeficiency virus increased risk inhibitor Nirmatrelvir oxygen Pfizer progression Prophylaxis protease Protease inhibitor Ritonavir SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 supplemental oxygen tablets Treatment treatment of COVID-19 United Kingdom USA [DOI] 10.1007/s40265-022-01692-5 PMC 바로가기 [Article Type] Review
Mechanisms and clinical evidence to support melatonin’s use in severe COVID-19 patients to lower mortalityReview article Published on 2022-04-012022-10-05 Journal: Life sciences [Category] COVID19(2023년), SARS, 변종, 신약개발, 임상, [키워드] activity adaptive Adaptive immunity added antibody formation approved Cell clinical evidence clinical trial country COVID-19 downregulate driven by Emergency use ENhance FDA fraction help high mortality Host Host immune response immune reaction include Inflammation inhibit innate immune response Innate immunity intubation less limit lower mortality main protease medication Medicine melatonin Mortality Nirmatrelvir pandemic promote reduce reducing mortality Replication Ritonavir safety margin SARS-CoV-2 SARS-COV-2 infection seasonal flu severe COVID-19 severe COVID-19 patient severe COVID-19 patients severity significantly Support suppress the cytokine storm the SARS-CoV-2 therapy tracheal treat Treatment Viral virulence virus virus infection [DOI] 10.1016/j.lfs.2022.120368 [Article Type] Review article
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)Research article Published on 2022-04-012022-10-05 Journal: Thérapie [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome Adverse drug reaction Antiviral association clinician Combination complex Contact coronavirus Course cysteine protease draft drug drug monitoring drug-drug interaction Efficacy enhancer enzyme Final French guideline help high risk management Modification modifications MPro National Nirmatrelvir objective Participants patients treated Paxlovid Pfizer Pharmacodynamics pharmacokinetic pharmacokinetics Pharmacology Pragmatic Prevent primary care protease recommendation recommendations Result Ritonavir SARS-CoV-2 secure Society therapeutic therapeutic strategy Therapeutics Treatment [DOI] 10.1016/j.therap.2022.03.005 [Article Type] Research article